Combining naltrexone and prazosin in a single oral medication decreases alcohol drinking more effectively than does either drug alone

Alcoholism: Clinical and Experimental Research

Volumn 37, Issue 10, 2013, Pages 1763-1770

  Froehlich, Janice C ^a   Hausauer, Brett J ^a   Rasmussen, Dennis D ^b  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VA PUGET SOUND HEALTH CARE SYSTEM   (United States)

Author keywords

Alcoholism Treatment; Genetic Selection; Naltrexone; Prazosin

Indexed keywords

NALTREXONE; PRAZOSIN;

ALCOHOL CONSUMPTION; ALCOHOL USE DISORDER; ALCOHOLISM; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRINKING BEHAVIOR; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG HALF LIFE; FEMALE; FLUID INTAKE; LOW DRUG DOSE; MALE; MEDICATION COMPLIANCE; NONHUMAN; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PRIORITY JOURNAL; RAT; SINGLE DRUG DOSE;

RATTUS;

ALCOHOLISM TREATMENT; GENETIC SELECTION; NALTREXONE; PRAZOSIN;

ADMINISTRATION, ORAL; ADRENERGIC ALPHA-1 RECEPTOR ANTAGONISTS; ALCOHOL DRINKING; ALCOHOLISM; ANIMALS; DRUG COMBINATIONS; DRUG SYNERGISM; MALE; NALTREXONE; NARCOTIC ANTAGONISTS; PRAZOSIN; RATS; RATS, WISTAR; TREATMENT OUTCOME;

EID: 84884983399     PISSN: 01456008     EISSN: 15300277     Source Type: Journal    
DOI: 10.1111/acer.12148     Document Type: Article

References (55)

1. Anton RF, O'Malley SS, Ciraulo DA, Cisler RA, Couper D, Donovan DM, Gastfriend DR, Hosking JD, Johnson BA, LoCastro JS, Longabaugh R, Mason BJ, Mattson ME, Miller WR, Pettinati HM, Randall CL, Swift R, Weiss RD, Williams LD, Zweben A (2006) Combined pharmacotherapies and behavioral interventions for alcohol dependence. The COMBINE study: a randomized controlled trial. JAMA 295:2003-2017.
2. Aston-Jones G, Cohen JD (2005) An integrative theory of locus coeruleus-norepinephrine function: adaptive gain and optimal performance. Annu Rev Neurosci 28:403-450.
3. Auriac A, Azam J, Dumas JC, Roux G, Montastruc JL (1983) Role of alpha 1 adrenergic receptors in water balance in the rat. J Pharmacol 14:351-360.
4. Cicero TJ (1979) A critique of animal analogues of alcoholism, in Biochemistry and Pharmacology of Ethanol, Vol. 2 (Majchrowicz E, Noble EP eds), pp 533-560. Plenum Press, New York.
5. Croop RS, Faulkner EB, Labriola DF (1997) The safety profile of naltrexone in the treatment of alcoholism. Results from a multicenter usage study. The naltrexone usage study group. Arch Gen Psychiatry 54:1130-1135.
6. Fox HC, Anderson GM, Tuit K, Hansen J, Kimmerling A, Siedlarz KM, Morgan PT, Sinha R (2011) Prazosin effects on stress- and cue-induced craving and stress response in alcohol-dependent individuals: preliminary findings. Alcohol Clin Exp Res 36:351-360.
7. Froehlich JC (2010) What aspects of human alcohol use disorders can be modeled using selectively bred rat lines? Subst Use Misuse 45:1727-1741.
8. Froehlich JC, Harts J, Lumeng L, Li TK (1990) Naloxone attenuates voluntary ethanol intake in rats selectively bred for high ethanol preference. Pharmacol Biochem Behav 35:385-390.
9. Froehlich JC, Hausauer BJ, Federoff DL, Fischer SM, Rasmussen DD (2013) Prazosin reduces alcohol drinking throughout prolonged treatment and blocks the initiation of drinking in rats selectively bred for high alcohol intake. Alcohol Clin Exp Res doi: 10.1111/acer.12116 [Epub ahead of print].
10. Froehlich JC, Li TK (1991) Animal models for the study of alcoholism: utility of selected lines. J Addict Dis 10:61-71.
11. Froehlich JC, Li TK (1993) Opioid peptides, in Recent Developments in Alcoholism, Volume 11: Ten Years of Progress (Galanter M ed), pp 187-205. Plenum Publishing Co, New York.
12. Froehlich JC, Li TK (1994) Opioid involvement in alcohol drinking. Ann N Y Acad Sci 739:156-167.
13. Froehlich J, O'Malley S, Hyytiä P, Davidson D, Farren C (2003) Preclinical and clinical studies on naltrexone: what have they taught each other? Alcohol Clin Exp Res 27:533-539.
14. Fuller RK, Branchey L, Brightwell DR, Derman RM, Emrick CD, Iber FL, James KE, Lacoursiere RB, Lee KK, Lowenstam I, Maany I, Neiderhiser D, Nocks JJ, Shaw S (1986) Disulfiram treatment of alcoholism: a Veterans Administration cooperative study. JAMA 256:1449-1455.
15. Garbutt JC, Kranzler HR, O'Malley SS, Gastfriend DR, Pettinati HM, Silverman BL, Loewy JW, Ehrich EW, Vivitrex Study Group (2005) Efficacy and tolerability of long-acting injectable naltrexone for alcohol dependence: a randomized controlled trial. JAMA 293:1617-1625.
16. Gilman JM, Ramchandani VA, Davis MB, Bjork JM, Hommer DW (2008) Why we like to drink: a functional magnetic resonance imaging study of the rewarding and anxiolytic effects of alcohol. J Neurosci 28:4583-4591.
17. Gilpin NW, Richardson HN, Koob GF (2008) Effects of CRF1-receptor and opioid-receptor antagonists on dependence-induced increases in alcohol drinking by alcohol-preferring (P) rats. Alcohol Clin Exp Res 32:1535-1542.
18. Gonzales RA, Weiss F (1998) Suppression of ethanol-reinforced behavior by naltrexone is associated with attenuation of the ethanol-induced increase in dialysate dopamine levels in the nucleus accumbens. J Neurosci 18:10663-10671.
19. Goodman LS, Gilman A (2006) The Pharmacological Basis of Therapeutics (Brunton LL, Lazo JS, Parker KL eds). 11th ed. McGraw-Hill, Chicago, IL.
20. Hollister LE, Johnson K, Boukhabza D, Gillespie HK (1981) Aversive effects of naltrexone in subjects not dependent on opiates. Drug Alcohol Depend 8:37-41.
21. Hussain MA, Aungst BJ, Kearney A, Shefter E (1987) Buccal and oral bioavailability of naloxone and naltrexone in rats. Int J Pharm 36:127-130.
22. Kranzler HR, Van Kirk J (2001) Efficacy of naltrexone and acamprosate for alcoholism: a meta-analysis. Alcohol Clin Exp Res 25:1335-1341.
23. Krishnan-Sarin S, Portoghese PS, Li TK, Froehlich JC (1995) The delta2 opioid receptor antagonist naltriben selectively attenuates alcohol intake in rats bred for alcohol preference. Pharmacol Biochem Behav 52:153-159.
24. Krishnan-Sarin S, Wand GS, Li XW, Portoghese PS, Froehlich JC (1998) Effect of mu opioid receptor blockade on alcohol intake in rats bred for high alcohol drinking. Pharmacol Biochem Behav 59:627-635.
25. Krystal JH, Cramer JA, Krol WF, Kirk GF, Rosenheck RA, Veterans Affairs Naltrexone Cooperative Study 425 Group (2001) Naltrexone in the treatment of alcohol dependence. N Engl J Med 345:1734-1739.
26. Kushner MG, Abrams K, Borchardt C (2000) The relationship between anxiety disorders and alcohol use disorders: a review of major perspectives and findings. Clin Psychol Rev 20:149-171.
27. Laska EM, Meisner M, Siegel C (1994) Simple designs and model-free tests for synergy. Biometrics 50:834-841.
28. Le AD, Poulos XC, Harding S, Watchus J, Juzytsch W, Shaham Y (1999) Effects of naltrexone and fluoxetine on alcohol self-administration and reinstatement of alcohol seeking induced by priming injections of alcohol and exposure to stress. Neuropsychopharmacology 21:435-444.
29. Li TK, Lumeng L, Doolittle DP (1993) Selective breeding for alcohol preference and associated responses. Behav Genet 23:163-170.
30. Li TK, Lumeng L, Doolittle DP, McBride WJ, Murphy JM, Froehlich JC, Morzorati S (1988) Behavioral and neurochemical associations of alcohol seeking behavior. Excerpta Medica Internat Congr Ser 805:435-438.
31. Li TK, Lumeng L, McBride WJ, Waller MS (1979) Progress toward a voluntary oral consumption model of alcoholism. Drug Alcohol Depend 4:45-60.
32. Liles JH, Flecknell PA, Roughan J, Cruz-Madorran I (1997) Influence of oral buprenorphine, oral naltrexone or morphine on the effects of laparotomy in the rat. Lab Anim 32:149-161.
33. Malcolm R, O'Neil PM, Von JM, Dickerson PC (1987) Naltrexone and dysphoria: a double-blind placebo-controlled trial. Biol Psychiatry 22:710-716.
34. Mitchell JM, O'Neil JP, Janabi M, Marks SM, Jagust WJ, Fields HL (2012) Alcohol consumption induces endogenous opioid release in the human orbitofrontal cortex and nucleus accumbens. Sci Transl Med 4:116ra6.
35. Niv D, Nemirovsky A, Rudick V, Geller E, Urca G (1995) Antinociception induced by simultaneous intrathecal and intraperitoneal administration of low doses of morphine. Anesth Analg 80:886-889.
36. O'Malley SS, Froehlich JC (2003) Advances in the use of naltrexone: an integration of preclinical and clinical findings, in Recent Developments in Alcoholism XVI: Research on Alcoholism Treatment (Galanter M ed), pp 217-245. Kluwer Academic/Plenum Publishers, New York.
37. O'Malley SS, Jaffe AJ, Rode S, Rounsaville BJ (1996) Experience of a "slip" among alcoholics treated with naltrexone or placebo. Am J Psychiatry 153:281-283.
38. Oncken C, Van Kirk J, Kranzler HR (2001) Adverse effects of oral naltrexone: analysis of data from two clinical trials. Psychopharmacology 154:397-402.
39. Oryan S, Eidi M, Eidi A, Kohanrooz B (2003) Effects of α1-adrenoceptors and muscarinic cholinoceptors on water intake in rats. Eur J Pharmacol 477:123-127.
40. Osborn JW, Provo BJ, Montana JS III, Trostel KA (1993) Salt-sensitive hypertension caused by long-term α-adrenergic blockade in the rat. Hypertension 21:995-999.
41. Pettinati HM, O'Brien CP, Rabinowitz AR, Wortman SP, Oslin DW, Kampman KM, Dackis CA (2006) The status of naltrexone in the treatment of alcohol dependence: specific effects on heavy drinking. J Clin Psychopharmacol 26:610-625.
42. Pöch G, Holzmann S (1980) Quantitative estimation of overadditive and underadditive drug effects by means of theoretical, additive dose-response curves. J Pharmacol Methods 4:179-188.
43. Raskind MA (2009) Sustained recovery from chronic alcohol dependence with prazosin treatment of PTSD. Alcohol Clin Exp Res 33(Suppl):311A.
44. Raskind MA, Peskind ER, Kanter KD, Petrie EC, Radant A, Thompson CE, Dobie DJ, Rein RJ, Straits-Tröster K, Thomas RG, McFall MM (2003) Reduction of nightmares and other PTSD symptoms in combat veterans by prazosin: a placebo-controlled study. Am J Psychiatry 160:371-373.
45. Rasmussen DD, Alexander LL, Raskind MA, Froehlich JC (2009a) The α1-adrenergic receptor antagonist, prazosin, reduces alcohol drinking in alcohol-preferring (P) rats. Alcohol Clin Exp Res 33:264-272.
46. Rasmussen DD, Federoff D, Froehlich JC (2009b) Prazosin reduces alcohol drinking in an animal model of alcohol relapse. Alcohol Clin Exp Res 33:146A.
47. Shepard TA, Reuning RH, Aarons LJ (1985) Estimation of area under the curve for drugs subject to enterohepatic cycling. J Pharmacokinet Biopharm 13:589-608.
48. Simpson TL, Saxon AJ, Meredith CW, Malte CA, McBride B, Ferguson LC, Gross CA, Hart KL, Raskind M (2009) A pilot trial of the alpha-1 adrenergic antagonist, prazosin, for alcohol dependence. Alcohol Clin Exp Res 33:255-263.
49. Spanagel R, Montkowski A, Allingham K, Stöhr T, Shoaib M, Holsboer F, Landgraf R (1995) Anxiety: a potential predictor of vulnerability to the initiation of ethanol self-administration in rats. Psychopharmacology 122:369-373.
50. Stocker SD, Stricker EM, Sved AF (2001) Acute hypertension inhibits thirst stimulated by ANG II, hyperosmolality, or hypovolemia in rats. Am J Physiol Regul Integr Comp Physiol 280:R214-R224.
51. Tallarida RJ (2001) Drug synergism: its detection and applications. J Pharmacol Exp Ther 298:865-872.
52. Tallarida RJ, Stone DJ, Raffa RB (1997) Efficient designs for studying synergistic drug combinations. Life Sci 61:417-425.
53. Trendelenburg U (1962) The action of acetylcholine on the nictitating membrane of the spinal cat. J Pharmacol Exp Ther 135:39-44.
54. Volpicelli JR, Watson NT, King AC, Sherman CE, O'Brien CP (1995) Effect of naltrexone on alcohol "high" in alcoholics. Am J Psychiatry 152:613-615.
55. Walker BM, Rasmussen DD, Raskind MA, Koob GF (2008) The effects of α1-noradrenergic receptor antagonism on dependence-induced increases in responding for ethanol. Alcohol 42:91-97.